Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
CAS No. ———
[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)( ——— )
Catalog No. M41491 CAS No. ———
[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
-
NoteResearch use only, not for human use.
-
Brief Description[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
-
Description[Gly1,Ser3,22,Gln4,34,Thr6,Ala19,Tyr21,Ala23,31, Aib32]-Pancreatic Polypeptide (human)
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight4207.73
-
Molecular FormulaC183H281N57O54S2
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Steroid Receptor Co ...
Steroid Receptor Co - Factor Peptide
-
10-Hydroxyaloin B
The herbs of Aloe vera L.
-
12-Dihexadecanoyl-sn...
PE(14:0/14:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. PE(14:0/14:0) in particular consists of two chains of myristic acid at the C-1 and C-2 positions. The myristic acid moieties are derived from nutmeg and butter.
